JP Morgan initiates C4 Therapeutics at overweight
JP Morgan initiated coverage of C4 Therapeutics with an overweight rating, per Benzinga’s ratings-action roundup.
Story updates
07:15:52 PM UTC
SquawkNews
C4 Therapeutics Price Target Announced at $10.00/Share by JP Morgan